RECENT PRESS RELEASES

Study on compounding accuracy of high-risk medications wins ASHP Research Award.

Tucson, Arizona – December 3, 2009 – CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com) extends its congratulations to Dr. Jim Stevenson and members of his staff at the CS Mott Children’s Hospital of the University of Michigan Health System, among the best in the nation, recipients of the 2009 ASHP Literature Award for Pharmacy Practice Research. Their study assessed the sensitivity and specificity of the ValiMed Medication Validation System (MVS) when used to confirm the admixture of high-risk parenteral medications. In the paper they also reported that in the first 18 months of use they identified five major medical errors that would have otherwise caused substantial harm to patients (Read the report here.). Thanks to the courageous efforts of Dr. Stevenson and his staff, many Directors of Pharmacy around the world now better understand the reality that undetected, major errors in the compounding of high risk medications are happening today in many hospitals and a technological safety net (such as the ValiMed MVS) is needed to protect patients.

CDEX will be demonstrating the lifesaving capabilities of the ValiMed MVS at the ASHP Mid-Year Conference (Venetian Hotel & Sands Expo Center) in Las Vegas on December 7-9, 2009. Dennis Quaid, representing the Dennis Quaid Foundation, will provide a keynote address at the Conference. CDEX invites all those interested in medication safety to stop by Booth # 743 and learn how ValiMed MVS is saving lives in major hospitals today.

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at mphilips@cdex-inc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

ValiMed™ MVS should be required at all hospitals – Emily Jerry Foundation

Tucson, Arizona – December 14, 2009 – CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com) announces that it presented the lifesaving capability of its ValiMed™ MVS (Medication Validation System) with new onsite data collection options to a great number of interested hospital pharmacists and safety specialists at the Las Vegas ASHP Conference (December 7-9, 2009). Worldwide studies continue to show that human errors in the compounding of high-risk medications occur frequently and result in permanent harm to patients and that the diversion of medical narcotics is a continuing problem. ValiMed MVS is a technological safety net that provides protection for patients, pharmacists and hospitals.

“I saw the ValiMed MVS demonstrated at the ASHP Conference and my conclusions are that it should be required at all hospitals – technology like this could have prevented the death of my daughter,” said Chris Jerry, President of the Emily Jerry Foundation (www.emilyjerryfoundation.org). “At the Conference, Dennis Quaid talked about the frequency of human errors and the need for technology to protect against them. From what I have seen, ValiMed is the only technology available today that prevents harm to patients from human errors in the compounding of high-risk medications. I believe that those hospitals which have adopted the ValiMed MVS as part of their Medication Safety Programs have set the standard of care and all hospitals should follow suit.”

“With the new policy of zero tolerance to medication errors announced by the Joint Commission the interest in ValiMed MVS was high -- human errors happen,” said Greg Firmbach, CDEX Senior VP. “We had our largest number of CDEX representatives ever at a conference and presented the ValiMed MVS capabilities to the largest number of hospital representatives ever at the booth. It looks like 2010 is stacking up to be an exciting year as hospital budgets are beginning to loosen and the ValiMed MVS Pay-Per-Use Pricing gets into full swing.”

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at mphilips@cdex-inc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Tucson, Arizona – December 2, 2009 – CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com) CEO and Chairman, Malcolm Philips, reviews CDEX’s performance through 2009 and sets the stage for 2010 in the “CEO Corner” of the CDEX Web Site. Mr. Philips reflected upon CDEX’s progress through the global economic downturn of 2009, concluding that based on recent sales activity 2010 will be a year of record placements of ValiMed™ MVS units, driven by improving economic conditions and the recent introduction of the “Pay Per Use” pricing plan for hospitals. The list of world class hospitals that have made ValiMed MVS a part of their Medication Safety and Narcotic Return Validation Programs continues to grow and lives are being saved. In addition, Tim Shriver, CDEX COO, provides a management briefing update on technological advancements in the CDEX product lines. For a complete review of the briefings, please go to the “CEO Corner” of the Management Briefing section of the CDEX Web Site (www.cdexinc.com).

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at mphilips@cdex-inc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Tucson, Arizona – December 1, 2009 – CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com) will demonstrate its ValiMed™ MVS with new onsite data collection options at the ASHP Conference (Venetian Hotels & Sands Expo Center) in Las Vegas on December 7-9, 2009. Dennis Quaid, representing the Dennis Quaid Foundation, will provide a keynote address at the Conference. CDEX invites all those interested in medication safety to stop by Booth # 743 and learn how ValiMed MVS is saving lives in major hospitals today.

“The ASHP Mid-Year meeting presents an opportunity for CDEX to inform the Directors of Pharmacy from the nation’s hospitals about the benefits of incorporating the ValiMed MVS into their pharmacy workflow,” said Greg Firmbach, CDEX Senior VP. “ValiMed™ MVS is increasing overall patient safety as a final check in the prevention of human error in the compounding of high-risk medications and as the central validation point for the disposal of narcotics as part of a narcotic diversion prevention program.”

Worldwide studies continue to show that human errors in the compounding of high-risk medications occur frequently and result in permanent harm to patients throughout the world and that the diversion of medical narcotics is a continuing problem. ValiMed™ MVS is a technological safety net that provides protection for patients, pharmacists and hospitals.

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at mphilips@cdex-inc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

ABMI GSA Contract now includes CDEX Products for Government Sales..

Tucson, Arizona and Sacramento, California – November 23, 2009 – CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com) and All Business Machines, Inc. (“ABMI”) (www.abmicorp.com) announce that the ValiMed™ MVS (Medication Validation System) and ID2 Meth Scanner™ product lines by CDEX have been placed on the ABMI GSA Contract Schedule. ValiMed MVS puts a technological safety net between the patient and errors made in the compounding of high risk medications and guards against narcotic diversion. Both are now available to the Government markets through the ABMI GSA Schedule. Medical studies such as the March 12, 2009 Study published in the British Medical Journal (BMJ 2009;338:b814, see March 16, 2009 CDEX Press Release [Scroll further down in this page to read.]) demonstrate that human errors in compounding of high-risk medications occur all too frequently and result in permanent harm to patients. *[This Press Release on the CDEX Web Site differs from the original Press Release in that it places the foregoing statement in the body of information provided by CDEX and cites a reference study in support of the statement.].

“ValiMed MVS provides an answer that is saving lives today,” said Karl Ross, President of ABMI. “We are pleased to partner with CDEX in bringing this lifesaving product line, as well as the ID2 Meth Scanner, to the Government market on our GSA Contract Schedule. There has been a great deal of interest for both products and we now have a contract vehicle to make it happen.”

“We are very pleased to be on the GSA Schedule and look forward to working more closely with ABMI in Government markets,” said Malcolm Philips, CDEX CEO. “Interest in our two product lines continues to be strong. Being placed on the GSA Schedule is happening at the right time with a thawing in the economic markets. We see 2010 shaping up to be a very good year for CDEX sales.“

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ MVS product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at mphilips@cdex-inc.com.

About ABMI

ABMI Corporation is a Service-Disabled Veteran-Owned Small Business and an SBA certified HUB-Zone Corporation that has partnered with Fortune 500 Companies such as Grainger, Agilent Technologies, and Goodyear to manage procurement contract processes related to Public Policy Goal Attainment acquisitions. ABMI has a proven record of providing the highest quality products, with proven customer satisfaction, translating into a very strong reputation among Veteran Administration Hospitals and Federal Agencies. For more information see www.abmicorp.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Major presentations and seminars by CDEX and Virtus to health officials mark the launch of ValiMed in the Middle East.

Tucson, Arizona, and Abu Dhabi, U.A.E – November 16, 2009 CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com) and Virtus Trading LLC announce that Malcolm Philips, CEO of CDEX, and Anil Pinto, Executive Director at Virtus, recently met with senior officials of health ministries, hospital administrators and pharmacists and conducted seminars on Medication Safety to the medical communities in Abu Dhabi, Dubai, Kuwait and Saudi Arabia as part of the regional launch of the ValiMed™ Medication Validation System. Worldwide studies continue to show that human errors in the compounding of high-risk medications occur frequently and result in permanent harm to patients throughout the world. The seminars focused on actions to minimize mistakes and the ValiMed technological safety net that provides protection for patients, pharmacists and hospitals.

“The message presented in the seminars was very well received and we are confident that the Middle East will be a strong market for ValiMed given current momentum on raising patient care standards across the region,” said Mr. Pinto. “We at Virtus and Virtus Al-Essa look forward to a very long and successful association with CDEX.”

“It was a privilege to talk to the pharmacy teams in this region, some of the best in the world, and it was reinforced to me that compounding errors and their devastating aftermath know no geographical boundaries,” said Mr. Philips. “We are honored to partner with Virtus in bringing the ValiMed technology to hospitals in this region. They share with CDEX and its growing number of ValiMed clients a passion for patient safety.”

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at mphilips@cdex-inc.com.

About Virtus

Drawing on over 30 years of business experience in Kuwait, and our commitment to the healthcare industry in the Gulf, Virtus Trading LLC was established with the objective of “Making the difference” on a regional basis. Our range of activities involves supplying products, installation, providing application support, clinical support and maintenance for medical and analytical needs. We can deliver complete solutions in facility engineering, providing mechanical piping, furniture, furnishing and equipment. Our ability to undertake this comprehensive range of activities in the region comes from more than 30 years of corporate experience in managing the Al-Essa Group of Companies, a premier company engaged in delivering total solution in the Healthcare and Scientific Sectors in Kuwait. We are proud of our unparalleled reputation for providing quality solutions, the result of a corporate ethos that has won recognition from our valued customers. More information about Al-Essa can be found at http://www.alessakuwait.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Tucson, Arizona – September 1, 2009 – CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com) Worldwide studies show that high-risk medication compounding errors in pharmacies continue to cause significant harm to patients and economic loss to hospitals. Geisinger Medical Center joins a growing list of world-class hospitals that are proactively addressing this issue by selecting the ValiMed™ Medication Safety System to assure the “Right Drug at the Right Dose” every time. ValiMed is used to validate accurate compounding of high-risk medications and to reduce the diversion of return narcotics in healthcare facilities.

“After reading the University of Michigan Health System study that documented ValiMed’s identification of five major medical mistakes over an 18 month period at one hospital, I knew that we needed to bring that technology in-house,” said John Jones, Geisinger Vice President, System Therapeutics. “We purchased two ValiMed units to provide additional assurance of accuracy of our compounding practices.”

“We are honored that Geisinger Medical Center selected ValiMed as part of its Medication Safety Program and look forward to working with John and his staff in integrating ValiMed into their daily practices,” said Greg Firmbach, Senior Vice President of CDEX.

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics and is distributed by companies such as Grifols, S.A. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine and is distributed by companies such as Decatur Electronics (part of Bowmer and Kirkland Limited). CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at mphilips@cdex-inc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Tucson, Arizona – September 1, 2009 – CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com) announces that Brigham and Women’s Hospital (Boston, MA) has selected the CDEX ValiMed™ Medication Safety System as part of its Medication Safety Program. Studies worldwide continue to show that mistakes in the compounding of high-risk medications occur and result in substantial harm to patients and economic loss to hospitals. In an 18-month University of Michigan Health System study, ValiMed identified 5 major medical errors (see http://www.ns.umich.edu/htdocs/releases/story.php?id=6255 ). ValiMed is used to validate the compounding of high-risk liquid medications in a pharmacy setting and also as a verification program to reduce the diversion of return narcotics in hospitals and other healthcare facilities.

“We selected two ValiMed units to provide additional assurance of accuracy for our robotic compounding and to validate the return of narcotics,” said William Churchill, Executive Director of Pharmacy. “Assuring the safety of our patients is job one at Brigham and ValiMed will help with that goal.”

“Brigham and Women’s Hospital joins the list of other world class hospitals that have selected ValiMed as part of their Medication Safety Program and we look forward to working with Bill and his staff to integrate ValiMed into their daily practices,” said Greg Firmbach, CDEX Senior Vice President.

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at mphilips@cdex-inc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Tucson, Arizona – August 26, 2009 – CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com) announces the signing of two multi-unit contracts for the placement of four new ValiMed Units in U.S. hospitals. One of the contracts was for the direct purchase of two units and one contract was a two unit Pay-Per-Use pricing plan that CDEX recently implemented to allow more hospitals to afford this life saving medication safety technology. ValiMed is used to validate “The Right Drug at The Right Dose” when high-risk liquid medications are compounded in a pharmacy setting and also as a verification program to reduce the diversion of return narcotics in hospitals and other healthcare facilities.

“The signing of our first Pay-Per-Use Agreement for multiple units marks the beginning of a new era that puts ValiMed in reach of every hospital no matter size or specialty,” said Greg Firmbach, Senior Vice President of CDEX. “Pay-Per-Use pricing is an all inclusive turnkey approach to placing this life-saving technology with equipment, supplies and service all for $2.50 per test or less from the hospitals operating (not capital) budgets. We have brought in another sales consultant to accommodate the growing interest and enthusiasm in the marketplace for this innovative pricing model.”

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at mphilips@cdex-inc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Tucson, Arizona – August 24, 2009 – CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com) announces completion of development-phase testing of a new generation Meth Scanner™ that embodies cell-phone technology and multi-filter applications. The new generation Scanner will have a cell-phone-interactive readout that increases functionality to provide more options for the law enforcement community in its battle against methamphetamine use. In addition, the technological advancements of multi-filter integration will provide greater sensitivity and a platform for multi-drug applications for the Scanner. The ID2 Meth Scanner LE (Law Enforcement) is currently being distributed by Decatur Electronics to national Law Enforcement markets. Decatur Electronics, www.decaturradar.com, headquartered in Decatur, Illinois is also a leading manufacturer of radar speed detectors and in-car video surveillance equipment for law enforcement applications.

The August issue of the Law Enforcement Technology Magazine provides a report on the progress of the ID2 Meth Scanner (pages 46, 48-51). While the article features law enforcement applications, it also references the ID2 Meth Scanner PI (Property Inspection Model) in the context of field testing at a county public health department in Washington State of a Meth Scanner (PI) modified to meet the more restrictive Washington State methamphetamine remediation standards. The results of those and follow up tests will be very helpful in further understanding the limits of the Scanner PI Model’s sensitivity.

“The ID2 Meth Scanner is a revolutionary product that provides the law enforcement community with a new tool to help combat the growing problem of methamphetamine use,” said Tim Shriver, CDEX COO. “The ID2 Meth Scanner is rapidly evolving, with the help of government agencies such as the county public health department in Washington State, to meet the requirements of both law enforcement and property inspection applications. The Law Enforcement Technology Magazine article provides insight into our improvement process and the culture of our company.”

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at mphilips@cdex-inc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Tucson, Arizona – July 30, 2009 – CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com) the developers and marketers of the ValiMed™ Medication Validation System for the in-patient hospital pharmacy implemented a new and innovative pricing plan which allows hospitals to afford this life saving medication safety technology on a “Pay-Per-Use” basis.

“By also offering a Pay-Per-Use Pricing as an alternative to capital purchase, CDEX positions its ValiMed technology to be in reach of every hospital no matter size or specialty,” said Greg Firmbach, Senior Vice President of CDEX. “Pay-Per-Use pricing is an all inclusive turnkey approach to placing life-saving technology with equipment, supplies and service all for around $2.50 per test. The reaction in the marketplace has been very positive as hospitals are now reviewing the integration of multiple ValiMed units into their medication safety programs for only the cost of supplies, an operating budget item.”

ValiMed is used to validate “The Right Drug at The Right Dose” when high-risk liquid medications are compounded in a pharmacy setting and also as a verification program to reduce the diversion of return narcotics in hospitals and other healthcare facilities. CDEX expects demand to continue to build as the health system pharmacists, patient safety agencies and associations and the Joint Commission become more aware of the availability of ValiMed at these prices.

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at mphilips@cdex-inc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Tucson, Arizona – July 24, 2009 – CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com) announces that on July 16, 2009, Greg Firmbach, CDEX Senior Vice President, represented CDEX at the World Technology Network Summit and Awards. The World Technology Awards are presented each year to the outstanding innovators from each sector within the technology arena (see http://www.wtn.net/summit2009). CDEX, Inc was honored to be among an internationally renowned group of nominees from all parts of the globe. CDEX was nominated for the Award in Health & Medicine, won by the Mayo Clinic. Other winners in their categories included Amazon.com, Facebook, YouTube, Honda Motors and The Phoenix Mars Landed Team.

CDEX’s nomination was based on its life-saving ValiMed Medication Validation System which is now being deployed throughout major North American hospitals. ValiMed provides real-time validation of sterile compounded admixtures in today’s fast-paced hospital pharmacy. ValiMed is unique in its ability to provide validation of “The Right Drug at The Right Dose” in seconds before the medication is released to a patient.

“We are pleased that ValiMed is being recognized for its life-saving properties as a leading innovation in the healthcare sector,” said Mr. Firmbach. “We were honored to be considered alongside giants in technology innovation and I was proud to represent CDEX and discuss our technology with inventors and scientist from the United States, the Georgian Republic, Germany, France and even the President of Rwanda.”

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at mphilips@cdex-inc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

TUCSON, AZ – June 24, 2009 - CDEX Inc. (OTCBB: CEXI) announces the resignation of General Robert H. Foglesong, U.S. Air Force (Retired), from its Board of Directors, effective June 24, 2009. General Foglesong (ret) has served on the Board of Directors since May 2008 and resigns in order to spend more time dealing with issues critical to his family.

“I regret having to leave the Board at this time, but my personal family situation dictates my resignation from a number of Boards that I was serving on,” said General Foglesong (ret). “I continue to be excited about the CDEX technology and its applications to patient safety and law enforcement. I wish Malcolm and the company every success going forward.”

“I am disappointed to see General Foglesong leave the CDEX Board but I understand his reasons. As a Board member he has challenged executive management in both business and technical directions,” said Malcolm Philips, CDEX Chairman. “General Foglesong leaves the Board and this Company better by his presence and involvement. We wish him well in the future and look forward to tapping into his advice periodically as we go forward.”

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2 ™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at mphilips@cdex-inc.com.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the Protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Sec. There is no obligation to publicly update any forward-looking statements.

Tucson, Arizona – June 23, 2009 – CDEX Inc. (OTCBB: CEXI) announces that the Company’s progress, response to the global economy, its two product lines, its recently filed 2QFY0910Q and other subjects are discussed by CEO Malcolm Philips in the “CEO Corner” of our website at www.cdexinc.com.

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at mphilips@cdex-inc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Tucson, Arizona – May 26, 2009 - CDEX Inc. (OTCBB:CEXI) www.cdexinc.com, announces that effective June 1, 2009, it has taken additional steps to streamline its organization in response to the downturn in the global economy. The Board of Directors unanimously approved a plan which calls for a selective reduction in expenses, while maintaining full support of existing and new customers. As part of the expense reduction, salary levels have been adjusted for all employees, including new employment agreements, with the CEO to provide services at no pay and for the COO to receive an annual salary of $25,000. While the Company will continue to expand its ValiMed™ and ID2™ product lines, research into new product lines will be curtailed, pending market conditions.

“The plan, approved unanimously by the Board, has been funded by some of our largest shareholders and has the full support of our largest creditor, Gemini Master Fund,” said Malcolm Philips, CDEX CEO. “This plan is the least dilutive to all existing stockholders, allows CDEX to pursue additional investment and management options, and provides focus on supporting existing customers and acquiring new customers. We are appreciative of our vendors, shareholders, customers, distributors and employees for working with us to implement this plan.”

“As a result of the Pay per Use Plan that I initiated in January 2009 to respond to tightened hospital capital budgets, we are now in the process of closing new deals with world class hospitals,” said Greg Firmbach, Medication Safety Division VP. “During this economic downturn, the interest in ValiMed has continued to grow with existing customers looking to add additional units and new customers outfitting their pharmacies with multiple units for quality assurance of the sterile compounded end products and trend programs for narcotic return validation. I fully expect ValiMed placements in CY09 will exceed placements in CY08 and we are looking forward to a banner 2010.”

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2 ™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, visit www.cdexinc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Methamphetamine tests conducted in buildings, trailers, a children's dance studio, and cars brought in voluntarily by local citizens for inspection.

Tucson, Arizona - April 20, 2009 – CDEX Inc. (OTCBB: CEXI) www.cdexinc.com announces that in inspections with the Island County Public Health Department in Washington, the ID2 Meth Scanner™ identified methamphetamine contamination in buildings, trailers, used cars at a dealership, and a children's dance studio. In addition, the Scanner found methamphetamine in automobiles voluntarily brought for inspection by local citizens. The ID2 Meth Scanner is a handheld, battery-operated device that quickly detects trace quantities of methamphetamine. The inspections were held during a demonstration of the Meth Scanner which had been requested by Marie Piper, the County's Environmental Health Specialist. The tests, being confirmed by laboratory analysis, were observed by a number of government officials, methamphetamine remediation experts, and the media, e.g., KOMO Channel 4 in Seattle (http://www.komonews.com/news/local/43074567.html?video=YHI&t=a).

"The ID2 Meth Scanner was easy to work with and provided almost immediate results," said Ms. Piper. "We inspected areas where our police department had alerted us to the possibility of methamphetamine contamination. Earlier, we had one case where a pregnant woman unsuspectingly bought a house where meth contamination was present and her baby was born with meth-indicative health issues. So, we react to these police alerts as quickly as possible to protect our citizens. The Meth Scanner could give us that quick reaction capability that we need."

"When Ms. Piper called seeking information concerning the Meth Scanner, it was clear that her Department was well ahead of most other government jurisdictions," said Tim Shriver, Jr., CDEX Director of Security Division Sales. "The cooperation between their law enforcement and public health departments is very good, and that equates to rapid action that serves to protect the public from the adverse health impacts of methamphetamine exposure. We are proud that the ID2 Meth Scanner will be able to play a role in that battle."

While CDEX distributes the Meth Scanner to the Property Inspection markets (see www.cdexinc.com), Decatur Electronics (www.decaturradar.com,) is the exclusive distributor of the ID2 Meth Scanner to the law enforcement markets in North America (see http://www.decaturradar.com/decatur/news_profile.php?id=55).

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2 ™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, visit www.cdexinc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

CDEX also ships Meth Scanners purchased by the Bureau of Indian Affairs

Tucson, Arizona - April 15, 2009 – CDEX Inc. (OTCBB: CEXI) www.cdexinc.com, announces that today it shipped the first ID2 Meth Scanners™ sold by Decatur Electronics to Law Enforcement Clients. The ID2 Meth Scanner is a handheld, battery-operated device that detects trace quantities of methamphetamine while in the scan mode. Decatur Electronics (www.decaturradar.com) is the exclusive distributor of the ID2 Meth Scanner to the law enforcement market in North America and a nonexclusive worldwide distributor. For more information, please visit http://www.decaturradar.com/decatur/news_profile.php?id=55.

“We believe that this first shipment of ID2 Meth Scanners for Decatur clients signifies a major milestone as the Scanner expands its role in the fight against illegal drugs,” said Kris Pearson, Marketing Manager for Decatur Electronics.

“This fight is equally intense on Indian Reservations, which is why the Bureau of Indian Affairs elected to purchase Scanners for their use,” said Matt Stratton, CDEX’s Manager of Marketing Development. “As the dangers of methamphetamine use and passive exposure to meth become better understood, we believe that the property inspection markets including inspection of houses, apartments, hotels and used autos, will continue to grow at an accelerated pace.”

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2 ™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, visit www.cdexinc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Tucson, Arizona - April 14, 2009 – CDEX Inc. (OTCBB: CEXI) www.cdexinc.com announces that Dr. Jefferey Burgess, MD, has joined the CDEX Team as a consultant to support work on the ID2 product line relating to detection of illegal drugs including methamphetamine. Dr. Burgess is an associate professor and the Director of the Community, Environment and Policy Division at The University of Arizona (“UA”) Mel and Enid Zuckerman College of Public Health in Tucson, Arizona. His research includes respiratory toxicology, reduction of mining-related injuries, and hazardous materials exposures including arsenic and methamphetamine laboratories. Dr. Burgess is the Principal Investigator for the CDC-funded Arizona Center for Public Health Preparedness.

Dr. Burgess has worked with many state, national and international groups on issues involving the dangers of illegal drugs, including the Arizona Attorney General’s Committee on Meth and Kids (now Drug Endangered Children) and the National Working Group on Clean-up and Remediation of Methamphetamine Laboratories. He helped develop the meth lab cleanup standards that are currently used by the State of Arizona. Dr. Burgess received an MD and a MPH from the University of Washington and an MS in toxicology and industrial hygiene from UA.

“Dr. Burgess is an internationally recognized leader in the field of methamphetamine exposure and remediation and we are delighted that he has agreed to join the CDEX Team in our work of expanding the ID2™ product line, including the Meth Scanner™,” said Tim Shriver, CDEX COO. “As the dangers of exposure to meth and meth lab precursors become more widely known, interest in the Meth Scanner from the property inspection markets, including the government health services community has risen. Dr. Burgess will assist us in improving the Meth Scanner and other ID2 products to respond to this growing problem.”

The ID2 Meth Scanner is a handheld, battery-operated device that detects trace quantities of methamphetamine while in the scan mode. Decatur Electronics (www.decaturradar.com,) is the exclusive distributor of the ID2 Meth Scanner to the law enforcement market in North America and a nonexclusive worldwide distributor. For more information, please visit http://www.decaturradar.com/decatur/news_profile.php?id=55.

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2 ™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, visit www.cdexinc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

First CDEX Shipment of OEM ID2 Product Line – Decatur Electronics ID2 Meth Scanner™

Tucson, Arizona - April 9, 2009 – CDEX Inc. (OTCBB: CEXI) www.cdexinc.com, announces approval of the final design for the first generation Decatur Electronics ID2 Meth Scanner™ with initial shipment to Decatur Electronics scheduled within a week. The ID2 Meth Scanner is a handheld, battery-operated device that detects trace quantities of methamphetamine while in the scan mode. Decatur is the exclusive distributor of the ID2 Meth Scanner to the law enforcement market in North America and a nonexclusive worldwide distributor (see http://cdexinc.com/pages/pr_current.html). Decatur Electronics, www.decaturradar.com, headquartered in Decatur, Illinois is also a leading manufacturer of radar speed detectors and in-car video surveillance equipment for law enforcement applications.

“CDEX is pleased to partner with Decatur Electronics in the sales and distribution of the ID2 Meth Scanner,” said Tim Shriver, CDEX COO. “We believe that the ID2 product line, including the Meth Scanner, will be very successful in both the law enforcement and property inspection markets. This marks another first for the ID2 product line – supplying an OEM product to a world class distribution partner. As we continue to develop additional product lines from our patented technologies we will explore this distribution model where we can get more rapid expansion through known worldwide distribution partners such as Decatur and its parent company Bowmer & Kirkland, Ltd., www.bandk.co.uk.”

For more information regarding the ID2 Meth Scanner, please visit http://www.decaturradar.com/decatur/news_profile.php?id=55.

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts or illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, visit www.cdexinc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Tucson, Arizona - March 23, 2009 – CDEX Inc. (OTCBB: CEXI) announces that effective April 1, 2009, Dr. Wade Poteet will step down from his position as Principal Scientist and become a project consultant supporting CDEX on an as needed basis. Dr. Poteet, the Company’s 1QFY0910Q and other subjects are discussed by CEO Malcolm Philips in the “CEO Corner” of our website at www.cdexinc.com.

“As CDEX overcame the scientific hurdles associated with our product lines, two years ago we agreed that I would transition to a support role for the company allowing me more time to pursue other interests,” said Dr. Wade Poteet. “In January 2008 I started the transition by reducing my work schedule and, after passing my 65th birthday, will now complete the transition by going to a project based consulting role with the company. I am very proud of the progress of the entire CDEX Team over the past seven years in taking a technology from a dream to where we have two very good product lines making differences in peoples’ lives today. Those at CDEX are very much like family and I wish them well in the future.”

“Dr. Poteet is one of the founding leaders of CDEX,” said Malcolm Philips, founding CDEX CEO. “He has been very instrumental in moving the CDEX technology to a mature science that forms the basis for expansion of our current product lines and development of new applications. Wade combines a strong scientific mind with practical hands-on development, and is rounded out by his outside interests, including being a grandfather, rancher, member of his Church Choir, bible study leader and musician who has played over 2820 gigs in the Tucson area. It is that unique and humble personality that will be sorely missed in the office. We wish Wade well and know that we will continue to see him frequently.”

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, visit www.cdexinc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

ID2 Meth Scanner used by law enforcement agencies in a growing number of states to combat the spread of methamphetamine.

Tucson, Arizona - March 20, 2009 – CDEX Inc. (OTCBB: CEXI) announced today that the ID2 Meth Scanner sold by Decatur Electronics (http://www.decaturradar.com) has been used to fight the war against methamphetamine in a growing number of jurisdictions including Arizona, California, Tennessee and Iowa. The ID2 Meth Scanner is a handheld, battery-operated device that detects trace quantities of methamphetamine while in the scan mode.

“Since debuting at the October 2008 COPS West Tradeshow, the ID2 Meth Scanner has been involved with a growing number of law enforcement busts,” said Tim Shriver, Jr., CDEX Security Division Sales Manager. “The most recent involved a traffic stop where the driver had two bags of white substance, only one of which the Meth Scanner identified as methamphetamine. Upon further analysis, the Scanner had correctly identified the meth and correctly rejected the second bag which was a cutting agent to be used in conjunction with sale of the meth. This is typical of the reports that we are receiving regarding this initial phase of Meth Scanner use by police in the field. We are excited by the results and the growing interest in the ID2 Meth Scanner.”

For more information regarding the ID2 Meth Scanner, please visit http://www.decaturradar.com/decatur/news_profile.php?id=55.

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, visit www.cdexinc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

An international study of 27 countries concluded that errors in the administration of injected medications are a serious safety problem – ValiMed™ by CDEX is addressing this problem in a growing number of hospitals worldwide.

Tucson, Arizona - March 16, 2009 – CDEX Inc. (OTCBB: CEXI). A March 12, 2009 report published in the British Medical Journal (BMJ 2009;338:b814), concluded that based on evaluations of more than 1300 patients in intensive care units over a 24-hour period across 27 countries, including the US, the administration of intravenous medication is a very serious patient safety problem. The study revealed that almost one in five (19%) patients experienced one medication error and 14% experienced more than one error. The study also found that of the 441 patients affected, twelve suffered permanent harm including five deaths. Over 20% of the errors related to wrong drug or wrong dose, which accounted for a disproportionally higher percentage of the incidents of severe harm to patients and involved many types of drugs, including insulin for diabetics, sedatives and blood-clotting drugs.

“This study confirms findings in previous reports regarding medication errors in hospitals, which have consistently supported the need for the ValiMed System – to provide assurance of the right drug at the right dose every time,” said Pascal Pouligny, GM of CDEX’s Medication Safety Division. “In 2008 we made the decision to build a global distribution network for the ValiMed product line and this new study confirms the basis for our decision -- medication errors represent a global problem that is seriously harming patients every day and ValiMed provides a solution now. In a previously published study by C.S. Mott Children’s Hospital in the University of Michigan Health System, ValiMed identified five serious medication errors and ‘consistently validated the correct solution, while dependably detecting as invalid the wrong drug or concentrations that departed substantially from the targeted standard.’ (See Am J Health-Syst Pharm--Vol 65, pp 49-54, Jan 1, 2008.) Studies such as these published in major Medical Journals will definitely help our ongoing efforts to promote ValiMed as the new standard for safe compounding and delivery of high-risk medications,” added Pouligny.

About CDEX Inc.

About CDEX CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, visit www.cdexinc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Decatur, IL – Decatur Electronics, Inc. announced today it is adding a handheld meth detection device to its stable of law enforcement products.

The ID-2™ Meth Scanner offers a safe, easy way to identify substances that are methamphetamine or contain pseudoephedrine, a core chemical component of meth. The scanner was developed by CDEX, Inc. of Tucson, AZ. CDEX and Decatur signed a distribution agreement this week for Decatur to sell the scanner in the United States and internationally.

The scanner uses ultraviolet photoemission spectroscopy to detect trace molecular elements of the meth chemicals. Officers scan powdered substances or areas with powder that they suspect have been in contact with the meth components. The ID-2™ detects the unique chemical signatures of the meth or pseudoephedrine as they react to the ultraviolet light, said Kris Pearson, Director of Marketing for Decatur.

In the past, officers conducted in-the-field tests where they mixed suspected drug substances with testing chemicals. The ID-2™ scanner weighs less than 2 pounds and runs on rechargeable batteries for over 8 hours. A laser pointer aids in accurately locating and scanning substances or an area.

“This new technology is one of the most exciting product offerings for law enforcement in recent years,” Pearson said. “Officers no longer have to physically handle the meth products or chemicals. They can within seconds determine whether a substance is meth or if it needs to be reassessed as something else. Every agency that has tested these scanners has expressed excitement at the opportunity of using them.”

A 2009 Rand Corp. study quantified the cost of meth abuse in the United States at $23 billion. The National Survey on Drug Use and Health calculates there were more than 700,000 users of methamphetamine aged 12 or older just two years ago.

Rates of methamphetamine use among persons aged 12 years or older were the highest in the Western United States (1.6 percent), followed by the South (0.7 percent), Midwest (0.5 percent), and Northeast (0.3 percent) regions of the country. Many of these are supplied through home-grown meth labs that are extremely dangerous due to the chemicals involved in the manufacturing of the illicit drug.

“The scanner allows law enforcement officers to confirm their professional training, experience and decisions regarding the presence of illegal substances,” Pearson said. “The ID-2 detects methamphetamine or pseudoephedrine almost anywhere. These trace amounts are measured as 1/10,000th of a gram and are barely visible or may be invisible to the naked eye.”

CDEX and Decatur are committed to providing the technical support necessary to combat any legal challenges to the technology’s validity and accuracy. This technology and its use are vital to helping police safely fight the war on drugs, Pearson said. Both companies also committed to coordinating the development of other drug and detection products for law enforcement.

CDEX is a technology development company that manufactures and globally distributes chemical detection products in the medication safety and security markets. The company’s Valimed™ product line provides life-saving validation of high-risk medications and returned narcotics.

Decatur Electronics is located in Decatur, IL and has engineering facilities in Colorado. It has been designing and manufacturing traffic radar for over 50 years, having created the first police radar in 1955. Their police radar is used by law enforcement and military throughout the world. Decatur also manufactures OnSite speed and message trailers as well as the Shadow 800 In Car Video System.

For more information about Decatur Electronics and its products, see www.decaturradar.com or call (800) 428-4315.

Leading supplier of electronic devices to law enforcement agencies will market the methamphetamine scanner globally.

Tucson, Arizona – February 25, 2009 - CDEX Inc. (OTCBB:CEXI) www.cdexinc.com, announces the signing of a three-year Master Distribution Agreement with Decatur Electronics, Inc. to market its ID2 Meth Scanner and future illicit drug detection devices on a global basis. The Agreement provides an exclusive marketing right to Decatur in the USA and Canadian markets and on a non-exclusive basis worldwide. Decatur will market to law enforcement agencies at federal, state and local levels, prison and jail facilities, Department of Defense and Homeland Security agencies..

Decatur Electronics, www.decaturradar.com, headquartered in Decatur, Illinois is a leading manufacturer of radar speed detectors and in-car video surveillance equipment for law enforcement applications. Decatur was recently purchased by Bowmer & Kirkland, Ltd., www.bandk.co.uk, a U.K.-based, international holding company with extensive positions in global security markets. B&K annual sales exceed $1.5 billion.

Kris Pearson, Director of Marketing for Decatur, talked about the partnership. “The ID2 Meth Scanner brings an exciting new technology to Decatur Electronics’ product offerings. We are continuously seeking new ways to help our law enforcement partners and the technology provided by CDEX elevates this commitment. The ID2 is a safer, highly reliable device that police and others can use to detect illicit drugs. Decatur also eagerly anticipates new product development and ongoing product enhancements with CDEX. This technology will provide new applications for our law enforcement partners. We look forward to bringing the ID2 Meth Scanner and other CDEX products to our more than 18,000 police, school, military, and other security customers worldwide.“

Steve Schmidt, VP CDEX Security Division, emphasized the significance of the Agreement. “We are very excited about this development for the future of our illicit drug detectors business. Decatur is a perfect partner for CDEX, based on their track record, market presence and aggressive growth strategies. They developed the first police speed radar device more than 50 years ago and have been the market leader since. They are an ISO-9001 certified manufacturer and known for quality products and service. We are particularly impressed with Decatur’s large, nationwide direct sales force whose members nearly all have a law enforcement background. They are excited about selling the ID2 Meth Scanner following a substantial market trial and testing period and are enthused about additional future products, including the ID2 Narcolyzer™, which is in final development stages.”

Mr. Schmidt went on to say, “Decatur is a Federal GSA supplier and very savvy about developing case law for their products. The ID2 Meth Scanner will be co-branded by CDEX and Decatur and will be featured at Decatur trade shows and in marketing collateral and promotions. Decatur will introduce our products to their international operations around the world through B&K.”

About CDEX Inc.

About CDEX CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2 ™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in SEC filings. For more information, visit www.cdexinc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

TUCSON, AZ—February 17, 2009 —CDEX Inc. (OTCBB: CEXI) filed its FY08 10KSB on February 13; FY08 accomplishments included record revenues (65% above FY07), 74% gross margins (65% in FY07), international expansion of the ValiMed™ product line, more than doubling of the ValiMed hospital client base, introduction of a new product line (ID2 Meth Scanner™), and domestic and international sales of both ValiMed and the ID2 Meth Scanner.

“FY08 was a year of positioning and great accomplishments for CDEX,” said Malcolm Philips, CDEX CEO. “Even while we expanded significantly our existing ValiMed product line, introduced the new ID2 product line, and positioned ourselves for the future by increased R&D spending, we still reduced our net operating loss by over 18%. While the global economic downturn presents major challenges for every company, including CDEX, we are moving in the right direction and fully expect to be cash flow positive by the last quarter of 2009 – our next major goal.” (See expanded comments regarding FY08 in the Management Briefing Section of the CDEX Web Site at www.cdexinc.com.)

About CDEX Inc.

About CDEX CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2 ™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must raise additional funds as stated periodically in its SEC filings. For more information, visit www.cdexinc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Next Generation ValiMed™ model introduced to North American Markets at ASHP Event

TUCSON, AZ — January 5, 2009 — CDEX Inc. (OTCBB: CEXI) introduced the ValiMed™ Model CCT to the North American healthcare markets at the December ASHP conference in Orlando, Florida. The CCT was earlier introduced to the European healthcare markets at the annual SNPHPU conference in Toulouse, France. (See related 8/21/08 and 9/23/08 press releases at www.cdexinc.com.) Going forward, the ValiMed CCT will be CDEX’s worldwide Medication Safety and Narcotics Return System platform, replacing the ValiMed Model VM.

The CCT validates the compounding of high risk medications and return narcotics in hospital pharmacies. It uses the same technologies employed in the VM, currently installed at hospitals around the world, but with a smaller footprint, enhanced sensitivity, comprehensive reporting tools and networking capabilities. (See the Medication Safety section of our web site, www.cdexinc.com).

“The ASHP conference attracted over 20,000 attendees from 86 countries and was truly a success for our Company,” stated CDEX CEO and Chairman Malcolm Philips. “Greg Firmbach, recently promoted to VP of our Medication Safety Division for North America, led the CDEX Team at the conference. Greg has more than 25 years of management experience in the healthcare arena and will provide good leadership as we continue with our global marketing efforts.”

“CDEX was the only exhibitor featuring a technology that directly validates the accuracy of compounded high risk medications or return narcotics,” said Mr. Firmbach. “Patients across the globe die every day from compounding errors. ValiMed tackles this problem directly by assuring that patients receive The Right Drug at the Right Dose! That is why our booth was busy from the opening until the closing bell. This interest generated a number leads for continuation of our year over year ValiMed revenue growth into 2009.” (Mr. Firmbach’s Management Briefing and bio are on our web site at www.cdexinc.com.)

About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2 ™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must raise additional funds as stated periodically in its SEC filings. For more information, visit www.cdexinc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the Securities and Exchange Commission. There is no obligation to update any forward-looking statements.